Suppr超能文献

使用市售支架移植物对高手术风险患者的腹主动脉瘤进行血管内治疗。

Endovascular treatment of abdominal aortic aneurysms in high-surgical-risk patients using commercially available stent-grafts.

机构信息

Department of Vascular and Endovascular Surgery, Universidade Positivo, Curitiba, Paraná, Brazil.

出版信息

J Endovasc Ther. 2010 Feb;17(1):89-94. doi: 10.1583/09-2872.1.

Abstract

PURPOSE

To analyze the initial and long-term results of endovascular aneurysm repair (EVAR) in high-surgical-risk patients (i.e., age > or =80 years, serum creatinine level > or =3 mg/dL, severe pulmonary dysfunction, severe cardiac dysfunction).

METHODS

From April 2002 to June 2009, 50 consecutive high-surgical-risk patients (42 men; mean age 74.0+/-8.7, range 54-91) with an abdominal aortic aneurysm (AAA; mean diameter 64.8 mm) who were treated electively using a bifurcated aortic endograft (32 Excluder, 18 Zenith) were entered in a prospective registry. Thirty-five (70%) patients were classified ASA III and 15 (30%) were ASA IV. High-risk status was corroborated using the Customized Probability Index (CPI). Primary endpoints were operative mortality and long-term survival; secondary endpoints were the frequency of reintervention, evolution of the aneurysm sac, and rates of primary and secondary patency and rupture.

RESULTS

The mean CPI score was 11.04+/-6.3. Operative mortality was 2% (1/50). There were 4 endoleaks, 1 case of endotension, and 1 endograft limb occlusion. Two patients required reintervention during the mean follow-up of 35.6 months. Survival at 3 years was 94%. Primary and secondary patency rates at 3 years were 98% and 100%, respectively. There were no ruptures.

CONCLUSION

Initial and long-term results with endovascular treatment of AAA in high-surgical-risk patients were satisfactory and appear to justify this approach in this patient population.

摘要

目的

分析高手术风险患者(即年龄≥80 岁、血清肌酐水平≥3mg/dL、严重肺功能障碍、严重心功能障碍)血管内动脉瘤修复(EVAR)的初始和长期结果。

方法

从 2002 年 4 月至 2009 年 6 月,50 例连续的高手术风险患者(42 例男性;平均年龄 74.0±8.7 岁,范围 54-91 岁)因腹主动脉瘤(AAA;平均直径 64.8mm)接受了分叉式主动脉内移植物(32 个 Excluder,18 个 Zenith)的选择性治疗,这些患者被纳入了一项前瞻性注册研究。35 例(70%)患者被分类为 ASA III,15 例(30%)为 ASA IV。高风险状态通过定制概率指数(CPI)得到证实。主要终点是手术死亡率和长期生存率;次要终点是再干预的频率、动脉瘤囊的演变以及一期和二期通畅率和破裂率。

结果

平均 CPI 评分为 11.04±6.3。手术死亡率为 2%(1/50)。有 4 例内漏,1 例内张力,1 例移植物分支闭塞。在平均 35.6 个月的随访中,有 2 例患者需要再次干预。3 年生存率为 94%。3 年的一期和二期通畅率分别为 98%和 100%。没有破裂。

结论

在高手术风险患者中,血管内治疗 AAA 的初始和长期结果令人满意,这似乎证明了在该患者人群中采用这种方法是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验